01 December 2005
Ann Transplant 2005; 10(3): 5-10 :: ID: 433648
Objectives: Acute rejection episodes negatively effect both short-term survival and development of graft vasculopathy.
Methods: We assessed the incidence and severity of acute rejection episodes under a new protocol using a monoclonal antibody daclizumab in the induction phase of immunosuppressive therapy. The study group B(26patients) was given daclizumab (1mg/kg), the control group A (25patients) was treated without daclizumab. There was no significant difference between the two groups in the important data. A total of first 10 EMB in every patient was classified according to the ISHLT recommendation. We also analysed the incidence of infections.
Results: During the first two months there was a significant lower incidence and/or severity of rejection episodes in the daclizumab group with p≤0,0016, 0,001 and 0,005 respectively.
Conclusions: Induction therapy with daclizumab significantly reduces the incidence of acute rejection episodes during the first two posttransplant
months in heart transplant recipients. It does not increase the risk of infection.
Keywords: Heart Transplantation, Endomyocardial Biopsy, Daclizumab, Immunosuppression, Rejection
Most Viewed Current Articles
26 Jan 2022 : Review articleRecurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models
Ann Transplant 2022; 27:e934924
24 Aug 2021 : Review articleNormothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original articleEfficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...
Ann Transplant 2021; 26:e933588